drugset
drugset / Trial / NCT00667901

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

NCT00667901 ↗

Phase 1 Terminated 15 enrolled University of Medicine and Dentistry of New Jersey National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.

Timeline

Start
2007-02
Primary completion
2008-10
Completion
2008-11

Outcome

Outcome not reported

Stopped (Enrollment): “All enrollment, treatment, follow-up \& data analysis completed”

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule — Oral

Indications

cutaneous melanoma